-
公开(公告)号：AU2003249012A1
公开(公告)日：2004-04-23
申请号：AU2003249012
申请日：2003-07-29
Applicant: ONCOTHERAPY SCIENCE INC
Inventor： KATAGIRI TOYOMASA , NAKAMURA YUSUKE
IPC: A61K38/00 , A61K39/00 , C07K14/47 , C12N15/12 , C12Q1/68 , G01N33/574 , C07K14/705 , C07K16/18 , G01N33/50 , A61K35/00
Abstract: Objective methods for detecting and diagnosing Chronic myeloid leukemia (CML) are described herein. In one embodiment, the diagnostic method involves the determining a expression level of CML-associated gene that discriminate between CML and normal cell. The present invention further provides methods of screening for therapeutic agents useful in the treatment of CML, methods of treating CML and method of vaccinating a subject against CML.
-
公开(公告)号：CA3070210A1
公开(公告)日：2019-01-24
申请号：CA3070210
申请日：2018-07-18
Applicant: UNIV TOKUSHIMA , ONCOTHERAPY SCIENCE INC
Inventor： KATAGIRI TOYOMASA , YOSHIMARU TETSURO , MIYAMOTO TAKASHI , OKAMOTO YASUHIDE
Abstract: The present invention provides a peptide having a structure in which a portion of a dominant-negative peptide of BIG3 which inhibits interaction between BIG3 and PHB2, is replaced by at least two stapling structures. The peptide according to the present invention has excellent cell growth inhibiting activity. The cell growth inhibiting activity is sustained for a long period of time, compared to a single-stapled peptide. Therefore, the peptide according to the present invention has a feature suitable for clinical applications in cancer therapy.
-
公开(公告)号：ES2381841T3
公开(公告)日：2012-06-01
申请号：ES04713982
申请日：2004-02-24
Applicant: ONCOTHERAPY SCIENCE INC
Inventor： NAKAMURA YUSUKE , KATAGIRI TOYOMASA , KUHARA MOTOKI
IPC: C07K16/28 , A61K39/395 , A61P35/00 , C07K16/30 , C12Q1/68 , G01N33/574 , G01N33/577
Abstract: Un anticuerpo o fragmento de anticuerpo dirigido contra la proteína Frizzled homólogo (FZD10), para usar en un método de tratamiento o prevención de sarcoma sinovial.
-
公开(公告)号：DE602004032556D1
公开(公告)日：2011-06-16
申请号：DE602004032556
申请日：2004-09-24
Applicant: ONCOTHERAPY SCIENCE INC
Inventor： NAKAMURA YUSUKE , KATAGIRI TOYOMASA , NAKATSURU SHUICHI
IPC: C12Q1/68 , C07K14/47 , C12N9/10 , G01N33/574
-
公开(公告)号：DE602005025231D1
公开(公告)日：2011-01-20
申请号：DE602005025231
申请日：2005-07-29
Applicant: ONCOTHERAPY SCIENCE INC
Inventor： NAKAMURA YUSUKE , KATAGIRI TOYOMASA , NAKATSURU SHUICHI
-
Patent Agency Ranking
公开(公告)号：DE60325628D1
公开(公告)日：2009-02-12
申请号：DE60325628
申请日：2003-09-12
Applicant: ONCOTHERAPY SCIENCE INC
Inventor： NAKAMURA YUSUKE , KATAGIRI TOYOMASA
IPC: C12Q1/68 , A61K38/00 , C07K14/47 , C07K14/82 , G01N33/574
Abstract: Objective methods for detecting and diagnosing pancreatic cancer (PNC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of PNC-associated gene that discriminates between PNC cells and normal cells. The present invention further provides methods of screening for therapeutic agents useful in the treatment of pancreatic cancer, methods of treating pancreatic cancer and method of vaccinating a subject against pancreatic cancer.
-
公开(公告)号：DE60325617D1
公开(公告)日：2009-02-12
申请号：DE60325617
申请日：2003-09-17
Applicant: ONCOTHERAPY SCIENCE INC
Inventor： NAKAMURA YUSUKE , KATAGIRI TOYOMASA
IPC: C12Q1/68 , A61K38/00 , C07K14/47 , G01N33/574
Abstract: Objective methods for detecting and diagnosing pancreatic cancer (PNC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of PNC-associated gene that discriminates between PNC cells and normal cells. The present invention further provides methods of screening for therapeutic agents useful in the treatment of pancreatic cancer, methods of treating pancreatic cancer and method of vaccinating a subject against pancreatic cancer.
-
公开(公告)号：AU2003264881A8
公开(公告)日：2004-04-23
申请号：AU2003264881
申请日：2003-09-22
Applicant: UNIV TOKYO , JAPAN PRESIDENT UNIV TOKYO , ONCOTHERAPY SCIENCE INC
Inventor： NAKAMURA YUSUKE , KATAGIRI TOYOMASA , NAKAGAWA HIDEWAKI , NAKATSURU SHUICHI
Abstract: The present application provides novel human gene MICAL2-PV whose expression is markedly elevated in prostate cancers. Furthermore, it provides polypeptides encoded by the gene as well as polypeptides encoded by PCOTH which expression was also discovered to be elevated in prostate cancers. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of prostate cancers, as target molecules for developing drugs against the disease, and for attenuating cell growth of prostate cancer.
-
公开(公告)号：AU2003263611A8
公开(公告)日：2004-04-23
申请号：AU2003263611
申请日：2003-09-22
Applicant: UNIV TOKYO , ONCOTHERAPY SCIENCE INC , JAPAN PRESIDENT UNIV TOKYO
Inventor： NAKAMURA YUSUKE , KATAGIRI TOYOMASA , NAKAGAWA HIDEWAKI , NAKATSURU SHUICHI
Abstract: The present application provides novel human gene MICAL2-PV whose expression is markedly elevated in prostate cancers. Furthermore, it provides polypeptides encoded by the gene as well as polypeptides encoded by PCOTH which expression was also discovered to be elevated in prostate cancers. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of prostate cancers, as target molecules for developing drugs against the disease, and for attenuating cell growth of prostate cancer.
-
公开(公告)号：AU2003263611A1
公开(公告)日：2004-04-23
申请号：AU2003263611
申请日：2003-09-22
Applicant: ONCOTHERAPY SCIENCE INC
Inventor： NAKAMURA YUSUKE , KATAGIRI TOYOMASA , NAKAGAWA HIDEWAKI , NAKATSURU SHUICHI
Abstract: The present application provides novel human gene MICAL2-PV whose expression is markedly elevated in prostate cancers. Furthermore, it provides polypeptides encoded by the gene as well as polypeptides encoded by PCOTH which expression was also discovered to be elevated in prostate cancers. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of prostate cancers, as target molecules for developing drugs against the disease, and for attenuating cell growth of prostate cancer.
-
-
-
-
-
-
-
-
-
Search Results
81
records
(took 0.029 seconds)
